Adial Pharmaceuticals, Inc. Overview
Pro stress-test →Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for the treatment and prevention of addiction and related disorders, with its lead product AD04, a serotonin-3 antagonist, currently in Phase 3 clinical trials for treating alcohol use disorder. The company is pursuing a precision medicine approach with significant regulatory tailwinds and strategic partnerships in development.
Strategic Profile
Pro stress-test →The company is advancing AD04 toward a pivotal Phase 3 program with refined clinical strategy, regulatory alignment, and manufacturing readiness. Recent federal appropriations directive on alternative clinical trial endpoints aligns with Adial's regulatory pathway for AD04, which targets Alcohol Use Disorder using a precision medicine approach.
Competitive Landscape
Pro stress-test →Adial operates in the addiction treatment therapeutics space competing against larger pharma with alcohol use disorder programs. Primary competitors include companies developing medications for AUD such as those with naltrexone, acamprosate, and other investigational serotonin-targeted approaches. The precision medicine genotype-targeting approach of AD04 differentiates Adial's positioning within this space.
Industry Context
Adial Pharmaceuticals, Inc. operates in Biopharmaceuticals - Addiction Treatment & Behavioral Health.
Key facts
Founded: 2010 · Headquarters: Glen Allen, Virginia · Employees: 5-7 · Revenue: Unknown · Market cap: $2.8M-$8.7M